Furthermore, polymorphisms in CYP2C9 considerably affect the pharmacokinetics and drug response variability of celecoxib, a medication used to treat osteoarthritis, rheumatoid arthritis, acute pain, and familial adenomatous polyposis. The gene discussed is CYP2C9; the disease is Familial adenomatous polyposis.